A Study of Patient Concerns and Treatment Satisfaction in Patients Being Treated With Finacea Foam for Rosacea

NCT03193372 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2200

Last updated 2020-04-01

No results posted yet for this study

Summary

To survey rosacea patients about their concerns, treatment satisfaction, and quality of life associated with their Finacea Foam treatment

Conditions

  • Rosacea

Interventions

DRUG

Azelaic Acid (Finacea Foam, BAY39-6251)

Finacea Foam, Active substance Azelaic acid

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY
  • LEO Pharma

    lead INDUSTRY

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-07-20
Primary Completion
2017-08-08
Completion
2017-11-15

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03193372 on ClinicalTrials.gov